Table of Content - Amyotrophic Lateral Sclerosis Market Size, Insights, Report 2032

Market Segmentation

Amyotrophic Lateral Sclerosis Type Outlook (USD Million, 2019-2030)

Sporadic ALS (SALS)

Familial ALS (FALS)

Amyotrophic Lateral Sclerosis Treatment Outlook (USD Million, 2019-2030)

Medication

Physical Therapy

Respiratory Therapy

Speech Therapy

Others

Amyotrophic Lateral Sclerosis End-User Outlook (USD Million, 2019-2030)

Specialty Centers

Research & Academic Institutes

Others

Amyotrophic Lateral Sclerosis Regional Outlook (USD Million, 2019-2030)

North America Outlook (USD Million, 2019-2030)
- North America Amyotrophic Lateral Sclerosis by Type
  - Sporadic ALS (SALS)
  - Familial ALS (FALS)
- North America Amyotrophic Lateral Sclerosis by Treatment
  - Medication
  - Physical Therapy
  - Respiratory Therapy
  - Speech Therapy
  - Others
- North America Amyotrophic Lateral Sclerosis by End-User
  - Specialty Centers
  - Research & Academic Institutes
  - Others
- US Outlook (USD Million, 2019-2030)
- US Amyotrophic Lateral Sclerosis by Type
  - Sporadic ALS (SALS)
  - Familial ALS (FALS)
- US Amyotrophic Lateral Sclerosis by Treatment
  - Medication
  - Physical Therapy
  - Respiratory Therapy
  - Speech Therapy
  - Others
- US Amyotrophic Lateral Sclerosis by End-User
  - Specialty Centers
  - Research & Academic Institutes
  - Others
- CANADA Outlook (USD Million, 2019-2030)
- CANADA Amyotrophic Lateral Sclerosis by Type
  - Sporadic ALS (SALS)
  - Familial ALS (FALS)
- CANADA Amyotrophic Lateral Sclerosis by Treatment
  - Medication
  - Physical Therapy
  - Respiratory Therapy
  - Speech Therapy
  - Others
- CANADA Amyotrophic Lateral Sclerosis by End-User
  - Specialty Centers
  - Research & Academic Institutes
  - Others

Europe Outlook (USD Million, 2019-2030)
- Europe Amyotrophic Lateral Sclerosis by Type
  - Sporadic ALS (SALS)
  - Familial ALS (FALS)
- Europe Amyotrophic Lateral Sclerosis by Treatment
  - Medication
  - Physical Therapy
  - Respiratory Therapy
  - Speech Therapy
  - Others
- Europe Amyotrophic Lateral Sclerosis by End-User
  - Specialty Centers
  - Research & Academic Institutes
  - Others
- Germany Outlook (USD Million, 2019-2030)
- Germany Amyotrophic Lateral Sclerosis by Type
  - Sporadic ALS (SALS)
  - Familial ALS (FALS)
- Germany Amyotrophic Lateral Sclerosis by Treatment
  - Medication
  - Physical Therapy
  - Respiratory Therapy
  - Speech Therapy
  - Others
- Germany Amyotrophic Lateral Sclerosis by End-User
  - Specialty Centers
  - Research & Academic Institutes
  - Others
- France Outlook (USD Million, 2019-2030)
- France Amyotrophic Lateral Sclerosis by Type
  - Sporadic ALS (SALS)
  - Familial ALS (FALS)
- France Amyotrophic Lateral Sclerosis by Treatment
  - Medication
  - Physical Therapy
  - Respiratory Therapy
  - Speech Therapy
  - Others
- France Amyotrophic Lateral Sclerosis by End-User
  - Specialty Centers
  - Research & Academic Institutes
  - Others
- UK Outlook (USD Million, 2019-2030)
- UK Amyotrophic Lateral Sclerosis by Type
  - Sporadic ALS (SALS)
  - Familial ALS (FALS)
- UK Amyotrophic Lateral Sclerosis by Treatment
  - Medication
  - Physical Therapy
  - Respiratory Therapy
  - Speech Therapy
  - Others
- UK Amyotrophic Lateral Sclerosis by End-User
  - Specialty Centers
  - Research & Academic Institutes
  - Others
- ITALY Outlook (USD Million, 2019-2030)
- ITALY Amyotrophic Lateral Sclerosis by Type
  - Sporadic ALS (SALS)
  - Familial ALS (FALS)
- ITALY Amyotrophic Lateral Sclerosis by Treatment
  - Medication
  - Physical Therapy
  - Respiratory Therapy
  - Speech Therapy
  - Others
- ITALY Amyotrophic Lateral Sclerosis by End-User
  - Specialty Centers
  - Research & Academic Institutes
  - Others

SPAIN Outlook (USD Million, 2019-2030)

Spain Amyotrophic Lateral Sclerosis by Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)

Spain Amyotrophic Lateral Sclerosis by Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others

Spain Amyotrophic Lateral Sclerosis by End-User
- Specialty Centers
- Research & Academic Institutes
- Others

Rest Of Europe Outlook (USD Million, 2019-2030)

Rest Of Europe Amyotrophic Lateral Sclerosis by Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)

REST OF EUROPE Amyotrophic Lateral Sclerosis by Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others

REST OF EUROPE Amyotrophic Lateral Sclerosis by End-User
- Specialty Centers
- Research & Academic Institutes
- Others

Asia-Pacific Outlook (USD Million, 2019-2030)
- Asia-Pacific Amyotrophic Lateral Sclerosis by Type
  - Sporadic ALS (SALS)
  - Familial ALS (FALS)
- Asia-Pacific Amyotrophic Lateral Sclerosis by Treatment
  - Medication
  - Physical Therapy
  - Respiratory Therapy
  - Speech Therapy
  - Others
- Asia-Pacific Amyotrophic Lateral Sclerosis by End-User
  - Specialty Centers
  - Research & Academic Institutes
  - Others

China Outlook (USD Million, 2019-2030)

China Amyotrophic Lateral Sclerosis by Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)

China Amyotrophic Lateral Sclerosis by Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others

China Amyotrophic Lateral Sclerosis by End-User
- Specialty Centers
- Research & Academic Institutes
- Others

Japan Outlook (USD Million, 2019-2030)

Japan Amyotrophic Lateral Sclerosis by Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)

Japan Amyotrophic Lateral Sclerosis by Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others

Japan Amyotrophic Lateral Sclerosis by End-User
- Specialty Centers
- Research & Academic Institutes
- Others

India Outlook (USD Million, 2019-2030)

India Amyotrophic Lateral Sclerosis by Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)

India Amyotrophic Lateral Sclerosis by Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others

India Amyotrophic Lateral Sclerosis by End-User
- Specialty Centers
- Research & Academic Institutes
- Others

Australia Outlook (USD Million, 2019-2030)

Australia Amyotrophic Lateral Sclerosis by Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)

Australia Amyotrophic Lateral Sclerosis by Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others

Australia Amyotrophic Lateral Sclerosis by End-User
- Specialty Centers
- Research & Academic Institutes
- Others

Rest of Asia-Pacific Outlook (USD Million, 2019-2030)

Rest of Asia-Pacific Amyotrophic Lateral Sclerosis by Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)

Rest of Asia-Pacific Amyotrophic Lateral Sclerosis by Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others

Rest of Asia-Pacific Amyotrophic Lateral Sclerosis by End-User
- Specialty Centers
- Research & Academic Institutes
- Others

Rest of the World Outlook (USD Million, 2019-2030)
- Rest of the World Amyotrophic Lateral Sclerosis by Type
  - Sporadic ALS (SALS)
  - Familial ALS (FALS)
- Rest of the World Amyotrophic Lateral Sclerosis by Treatment
  - Medication
  - Physical Therapy
  - Respiratory Therapy
  - Speech Therapy
  - Others
- Rest of the World Amyotrophic Lateral Sclerosis by End-User
  - Specialty Centers
  - Research & Academic Institutes
  - Others

Middle East Outlook (USD Million, 2019-2030)

Middle East Amyotrophic Lateral Sclerosis by Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)

Middle East Amyotrophic Lateral Sclerosis by Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others

Middle East Amyotrophic Lateral Sclerosis by End-User
- Specialty Centers
- Research & Academic Institutes
- Others

Africa Outlook (USD Million, 2019-2030)

Africa Amyotrophic Lateral Sclerosis by Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)

Africa Amyotrophic Lateral Sclerosis by Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others

Africa Amyotrophic Lateral Sclerosis by End-User
- Specialty Centers
- Research & Academic Institutes
- Others

Latin America Outlook (USD Million, 2019-2030)

Latin America Amyotrophic Lateral Sclerosis by Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)

Latin America Amyotrophic Lateral Sclerosis by Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others

Latin America Amyotrophic Lateral Sclerosis by End-User
- Specialty Centers
- Research & Academic Institutes
- Others

Leading companies partner with us for data-driven Insights

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

1 Executive Summary

2 Market Introduction

2.1 Definition 17

2.2 Scope of the Study 17

2.3 List of Assumptions 17

2.4 Market Structure 18

3 Research Methodology

3.1 Research Process 20

3.2 Primary Research 21

3.3 Secondary Research 22

3.4 Market Size Estimation 23

3.5 Forecast Model 23

4 Market Dynamics

4.1 Overview 25

4.2 Drivers 26

4.2.1 Growing Incidence of Amyotrophic Lateral Sclerosis (ALS) 26

4.2.2 Rising Geriatric Population 26

4.2.3 Growing Awareness about Amyotrophic Lateral Sclerosis 26

4.3 Restraints 27

4.3.1 High Cost of ALS Treatment 27

4.4 Opportunities 27

4.4.1 Increasing Strategic Collaborations of Major Companies and Research Institutes for the Development of ALS Treatment 27

5 Market Factor Analysis

5.1 Porter’s Five Forces Model 29

5.1.1 Bargaining Power of Suppliers 30

5.1.2 Bargaining Power of Buyers 30

5.1.3 Threat of New Entrants 30

5.1.4 Threat of Substitutes 30

5.1.5 Intense Rivalry 30

5.2 Value Chain Analysis 31

5.2.1 Raw Material Sourcing 31

5.2.2 Manufacturing 31

5.2.3 Distribution & Sales 31

5.2.4 Post-Sales Monitoring 32

5.3 Investment Feasibility Analysis 32

5.4 Pricing Analysis 32

6 Global Amyotrophic Lateral Sclerosis Market, by Type

6.1 Overview 34

6.2 Sporadic ALS 34

6.3 Familial ALS 35

7 Global Amyotrophic Lateral Sclerosis Market, by Treatment

7.1 Overview 37

7.2 Medication 38

7.3 Physical Therapy 39

7.4 Respiratory Therapy 39

7.5 Speech Therapy 40

7.6 Others 40

8 Global Amyotrophic Lateral Sclerosis Market, by End User

8.1 Overview 42

8.2 Hospitals 42

8.3 Specialty Centers 43

8.4 Research and Academic Institutes 44

8.5 Others 44

9 Global Amyotrophic Lateral Sclerosis Market, by Region

9.1 Overview 46

9.2 Americas 47

9.2.1 North America 49

9.2.1.1 US 51

9.2.1.2 Canada 53

9.2.2 Latin America 54

9.3 Europe 56

9.3.1 Western Europe 58

9.3.1.1 Germany 61

9.3.1.2 France 62

9.3.1.3 UK 64

9.3.1.4 Italy 65

9.3.1.5 Spain 67

9.3.1.6 Rest of Western Europe 68

9.3.2 Eastern Europe 70

9.4 Asia-Pacific 72

9.4.1 Japan 74

9.4.2 Australia 76

9.4.3 China 77

9.4.4 India 79

9.4.5 South Korea 80

9.4.6 Rest of Asia-Pacific 82

9.5 Middle East & Africa 84

9.5.1 Middle East 86

9.5.2 Africa 88

10 Company Landscape

10.1 Overview 91

10.2 Company Ranking 91

11 Company Profile

11.1 Ascend Laboratories LLC 94

11.1.1 Company Overview 94

11.1.2 Financial Overview 94

11.1.3 Products/Services Offered 94

11.1.4 SWOT Analysis 95

11.1.5 Key Developments 95

11.1.6 Key Strategy 95

11.2 Apotex Inc. 96

11.2.1 Company Overview 96

11.2.2 Financial Overview 96

11.2.3 Products/Services Offered 96

11.2.4 SWOT Analysis 96

11.2.5 Key Developments 96

11.2.6 Key strategy 96

11.3 Biogen 97

11.3.1 Company Overview 97

11.3.2 Financial Overview 97

11.3.3 Products/Services Offered 98

11.3.4 SWOT Analysis 98

11.3.5 Key Developments 98

11.3.6 Key strategy 98

11.4 Covis Pharma 99

11.4.1 Company Overview 99

11.4.2 Financial Overview 99

11.4.3 Products/Services Offered 99

11.4.4 SWOT Analysis 100

11.4.5 Key Developments 100

11.4.6 Key Strategy 100

11.5 Ionis Pharmaceuticals 101

11.5.1 Company Overview 101

11.5.2 Financial Overview 101

11.5.3 Products/Services Offered 101

11.5.4 SWOT Analysis 102

11.5.5 Key Developments 102

11.5.6 Key Strategy 102

11.6 ITF Pharma 103

11.6.1 Company Overview 103

11.6.2 Financial Overview 103

11.6.3 Products/Services Offered 103

11.6.4 Key Developments 103

11.6.5 SWOT Analysis 103

11.6.6 Key Strategy 103

11.7 Mitsubishi Tanabe Pharma America 104

11.7.1 Company Overview 104

11.7.2 Financial Overview 104

11.7.3 Products/Services Offered 105

11.7.4 SWOT Analysis 105

11.7.5 Key Developments 105

11.7.6 Key strategy 105

11.8 Mylan N.V. 106

11.8.1 Company Overview 106

11.8.2 Financial Overview 106

11.8.3 Products/Services Offered 107

11.8.4 SWOT Analysis 107

11.8.5 Key Developments 107

11.8.6 Key Strategy 107

11.9 Sanofi 108

11.9.1 Company Overview 108

11.9.2 Financial Overview 108

11.9.3 Products/Services Offered 108

11.9.4 SWOT Analysis 109

11.9.5 Key Developments 109

11.9.6 Key Strategy 109

11.10 Sun Pharmaceutical Industries Ltd 110

11.10.1 Company Overview 110

11.10.2 Financial Overview 110

11.10.3 Products/Services Offered 110

11.10.4 SWOT Analysis 111

11.10.5 Key Development 111

11.10.6 Key Strategy 111

12 Appendix

12.1 Discussion Blue Print 113

13 List of Tables

TABLE 1 MARKET SYNOPSIS 15

TABLE 2 LIST OF ASSUMPTIONS 17

TABLE 3 GLOBAL ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 34

TABLE 4 GLOBAL ALS MARKET FOR SPORADIC ALS, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 5 GLOBAL ALS MARKET FOR FAMILIAL ALS, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 6 GLOBAL ALS MARKET FOR TREATMENT, 2020–2027 (USD MILLION) 37

TABLE 7 GLOBAL ALS MARKET FOR MEDICATION, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 8 GLOBAL ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 38

TABLE 9 GLOBAL ALS MARKET FOR PHYSICAL THERAPY, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 10 GLOBAL ALS MARKET FOR RESPIRATORY THERAPY, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 11 GLOBAL ALS MARKET FOR SPEECH THERAPY, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 12 GLOBAL ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 42

TABLE 13 GLOBAL ALS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 14 GLOBAL ALS MARKET FOR SPECIALTY CENTERS, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 15 GLOBAL ALS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 16 GLOBAL ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 17 AMERICAS: ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 18 AMERICAS: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 48

TABLE 19 AMERICAS: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 48

TABLE 20 AMERICAS: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 48

TABLE 21 AMERICAS: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 49

TABLE 22 NORTH AMERICA: ALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 49

TABLE 23 NORTH AMERICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 50

TABLE 24 NORTH AMERICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 50

TABLE 25 NORTH AMERICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 50

TABLE 26 NORTH AMERICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 51

TABLE 27 US: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 28 US: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 52

TABLE 29 US: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 52

TABLE 30 US: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 52

TABLE 31 CANADA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 32 CANADA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 53

TABLE 33 CANADA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 54

TABLE 34 CANADA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 54

TABLE 35 LATIN AMERICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 36 LATIN AMERICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55

TABLE 37 LATIN AMERICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 55

TABLE 38 LATIN AMERICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 55

TABLE 39 EUROPE: ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 56

TABLE 40 EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 41 EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 57

TABLE 42 EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 57

TABLE 43 EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 58

TABLE 44 WESTERN EUROPE: ALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59

TABLE 45 WESTERN EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 46 WESTERN EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 60

TABLE 47 WESTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 60

TABLE 48 WESTERN EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 49 GERMANY: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 50 GERMANY: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 61

TABLE 51 GERMANY: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 62

TABLE 52 GERMANY: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 62

TABLE 53 FRANCE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 54 FRANCE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 63

TABLE 55 FRANCE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 63

TABLE 56 FRANCE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 57 UK: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 58 UK: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 64

TABLE 59 UK: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 65

TABLE 60 UK: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 65

TABLE 61 ITALY: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 62 ITALY: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 66

TABLE 63 ITALY: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 66

TABLE 64 ITALY: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 66

TABLE 65 SPAIN: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 66 SPAIN: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 67

TABLE 67 SPAIN: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 68

TABLE 68 SPAIN: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 68

TABLE 69 REST OF WESTERN EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 70 REST OF WESTERN EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 69

TABLE 71 REST OF WESTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 69

TABLE 72 REST OF WESTERN EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 69

TABLE 73 EASTERN EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 74 EASTERN EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 70

TABLE 75 EASTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 71

TABLE 76 EASTERN EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 71

TABLE 77 ASIA-PACIFIC: ALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72

TABLE 78 ASIA-PACIFIC: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 79 ASIA-PACIFIC: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 73

TABLE 80 ASIA-PACIFIC: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 73

TABLE 81 ASIA-PACIFIC: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 74

TABLE 82 JAPAN: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 83 JAPAN: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 75

TABLE 84 JAPAN: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 75

TABLE 85 JAPAN: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 75

TABLE 86 AUSTRALIA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 87 AUSTRALIA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 76

TABLE 88 AUSTRALIA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 77

TABLE 89 AUSTRALIA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 77

TABLE 90 CHINA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 91 CHINA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 78

TABLE 92 CHINA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 78

TABLE 93 CHINA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 78

TABLE 94 INDIA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 95 INDIA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 79

TABLE 96 INDIA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 80

TABLE 97 INDIA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 80

TABLE 98 SOUTH KOREA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 99 SOUTH KOREA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 81

TABLE 100 SOUTH KOREA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 81

TABLE 101 SOUTH KOREA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 81

TABLE 102 REST OF ASIA-PACIFIC: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 103 REST OF ASIA-PACIFIC: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 82

TABLE 104 REST OF ASIA-PACIFIC: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 83

TABLE 105 REST OF ASIA-PACIFIC: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 83

TABLE 106 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 84

TABLE 107 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 108 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 85

TABLE 109 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 85

TABLE 110 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 86

TABLE 111 MIDDLE EAST: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 112 MIDDLE EAST: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 87

TABLE 113 MIDDLE EAST: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 87

TABLE 114 MIDDLE EAST: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 87

TABLE 115 AFRICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 116 AFRICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 88

TABLE 117 AFRICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 89

TABLE 118 AFRICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 89

TABLE 119 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET: MAJOR PLAYER RANKING, 2020 91

14 List of Figures

FIGURE 1 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET: MARKET STRUCTURE 18

FIGURE 2 RESEARCH PROCESS OF MRFR 20

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES 23

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET 25

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET 29

FIGURE 6 VALUE CHAIN: GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET 31

FIGURE 7 GLOBAL ALS MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 34

FIGURE 8 GLOBAL ALS MARKET, BY TREATMENT, 2020 AND 2027 (USD MILLION) 37

FIGURE 9 GLOBAL ALS MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 42

FIGURE 10 GLOBAL ALS MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 46

FIGURE 11 AMERICAS: ALS MARKET, BY REGION, 2020 (%) 47

FIGURE 12 NORTH AMERICA: ALS MARKET, BY COUNTRY, 2020 (%) 49

FIGURE 13 EUROPE: ALS MARKET, BY REGION, 2020 (%) 56

FIGURE 14 WESTERN EUROPE: ALS MARKET, BY COUNTRY, 2020 (%) 58

FIGURE 15 ASIA-PACIFIC: ALS MARKET, BY COUNTRY, 2020 (%) 72

FIGURE 16 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY REGION, 2020 (%) 84

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

FEATURES	LICENCE TYPE
FEATURES	Single User	Multiuser Licence	Enterprise User
Price	$ 4,950	$ 5,950	$ 7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout The Organization.
Free Customization
Direct access to the Analyst
Deliverable Format
Deliverable Format
Platform Access
Discount on Your Next Purchase	10%	15%	10%
Printable Versions

Why Choose Market Research Future?

Leading companies partner with us for data-driven Insights